抗H因子抗体阳性溶血尿毒综合征7例分析

doi:10.6040/j.issn.1671-7554.0.2021.0589

摘要/Abstract

摘要： 目的抗H因子抗体阳性的溶血尿毒综合征是溶血尿毒综合征(HUS)中的严重亚型,通过探讨患儿的临床特点、治疗及转归情况,为临床诊治提供依据。方法回顾性收集2011年5月至2017年12月收治的7例抗H因子抗体阳性HUS患儿临床资料,其中男5例、女2例,5.83~13.5岁,平均7.93岁,分析其一般情况、前驱感染、临床特点、治疗及转归,并随访3~8年。结果前驱感染:发热、咳嗽等上呼吸道感染症状占57.14%(4/7),呕吐、腹痛等消化系统症状占71.42%(5/7);临床特点:所有患儿均抗H因子抗体阳性、ADAMTS13活性正常,H因子浓度2例正常,5例降低;7例均呈现中至重度贫血、血小板减少症、高胆红素血症、大量蛋白尿、严重的急性肾损害及低补体C3血症。3例行肾穿刺活检,3例行基因检测。治疗与转归:急性期7例患儿均早期给予丙种球蛋白、血浆置换联合大剂量甲强龙冲击治疗,后序贯口服糖皮质激素,1例死亡,6例缓解(平均治疗27.83 d)。5例因尿常规持续异常加用免疫抑制剂治疗。随访3~8年,4例完全缓解,2例部分缓解。4例复测抗H因子抗体2例转阴性,2例仍阳性。结论抗H因子抗体阳性HUS患儿临床表现重,急性期在对症支持治疗基础上,早期积极使用血浆置换、丙种球蛋白,并联合大剂量甲强龙冲击治疗,可迅速控制病情,续贯长疗程应用维持性免疫抑制治疗,可减少复发,延长患儿缓解期。抗H因子抗体和补体C3有可能作为预后监测指标。

关键词: 溶血尿毒综合征, 抗H因子抗体, 临床特点, 治疗, 随访

Abstract: Objective Anti-H factor antibody-positive hemolytic uremic syndrome(HUS)is a severe subtype of HUS. The clinical characteristics, treatment and outcome of children with such disease were discussed to provide reference for clinical diagnosis and treatment. Methods Clinical data of 7 patients with anti-H factor antibody-positive HUS during May 2011 and Dec. 2017 were retrospectively analyzed, including 5 male and 2 female, aged 5.83 to 13.5(mean 7.93)years. The general condition, pre-infection, clinical characteristics, treatment, outcome and 3-8-year follow-up results were analyzed. Results Pre-infection: upper respiratory tract infection symptoms such as fever and cough were discovered in 57.14%(4/7)patients; digestive system symptoms such as vomiting and abdominal pain manifested in 71.42%(5/7)patients. Clinical features: all children were positive for anti-H factor antibody, ADAMTS13 activity was normal, 2 cases of H factor titer were normal, and the other were decreased; All cases showed moderate to severe anemia, thrombocytopenia, hyperbilirubinemia, massive proteinuria, severe acute kidney damage, and low-complement C3. Renal biopsy was performed in 3 cases and genetic testing in 3 cases. Treatment and outcome: all patients in the acute phase were treated with Gamma globulin, plasma exchange and high-dose methylprednisolone, followed by oral glucocorticoids. The outcome was 1 death and 6 relief, with the mean treatment time of 27.83 days. Five patients were treated with immunosuppressive agents due to persistent abnormalities in urine routine. After 3-8 years of follow-up, 4 patients had complete remission and 2 had partial remission; of the 4 cases who repeated amti H factor antibody examination, 2 were negative and 2 were still positive. Conclusion Children with anti-H factor antibody-positive HUS have severe clinical manifestations. On the basis of symptomatic supportive therapy in the acute phase, early use of plasma exchange, Gamma globulin, combined with high-dose methylprednisol impact therapy, can quickly control the condition. Long-term application of immunosuppressive agents can reduce recurrence and prolong the remission period. H factor antibody and C3 may be used as indicators of prognostic monitoring.

Key words: Hemolytic uremic syndrome, Anti-H factor antibody, Clinical characteristics, Treatment, Follow-up

中图分类号:

R574

孔昕欣,孙书珍,李倩,陈元,周爱华,王莉,姚秀俊. 抗H因子抗体阳性溶血尿毒综合征7例分析[J]. 山东大学学报 (医学版), 2022, 60(4): 82-86.

KONG Xinxin, SUN Shuzhen, LI Qian, CHEN Yuan, ZHOU Aihua, WANG Li, YAO Xiujun. Analysis of 7 cases of anti-H factor antibody-positive hemolytic uremic syndrome[J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 82-86.

参考文献

[1] Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Hemolytic uremic syndrome [J]. The Lancet, 2017, 390(10095): 681-696.
[2] Raina R, Krishnappa V, Blaha T, et al. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment [J]. Ther Apher Dial, 2019, 23(1): 4-21.
[3] Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO)Controversies Conference [J]. Kidney Int, 2017, 91(3): 539-551.
[4] Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children [J]. Pediatr Nephrol, 2016, 31(1): 15-39.
[5] Song D, Liu XR, Chen Z, et al. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome [J]. Pediatr Nephrol, 2017, 32(5): 811-822.
[6] Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome [J]. Kidney Int, 2018, 94(2): 408-418.
[7] Blanc C, Togarsimalemath SK, Chauvet S, et al. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases [J]. J Immunol, 2015, 194(11): 5129-5138.
[8] 管娜, 刘晓宇, 姚勇, 等. 抗H因子自身抗体相关性溶血尿毒综合征临床特点、治疗及随访[J]. 中华儿科杂志, 2014, 52(3): 223-226.
[9] Loirat C, Frémeaux-Bacchi V. Anti-factor H autoantibody-associated hemolytic uremic syndrome: the earlier diagnosed and treated, the better [J]. Kidney Int, 2014, 85(5): 1019-1022.
[10] Puraswani M, Khandelwal P, Saini H, et al. Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database [J]. Front Immunol, 2019, 10: 1282. doi:10.3389/fimmu.2019.01282.
[11] Dragon-Durey MA, Blanc C, Garnier A, et al. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS [J]. Semin Thromb Hemost, 2010, 36(6): 633-640.
[12] Brocklebank V, Johnson S, Sheerin TP, et al. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland [J]. Kidney Int, 2017, 92(5): 1261-1271.
[13] Sinha A, Gulati A, Saini S, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children [J]. Kidney Int, 2014, 85(5): 1151-1160.
[14] Monteferrante G, Brioschi S, Caprioli J, et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome [J]. Molecular Immunology, 2007, 44(7): 1704-1708.
[15] Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome [J]. Blood, 2006, 108(4): 1267-1279.
[16] Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: Consensus guidelines [J]. Pediatr Nephrol, 2019, 34(8): 1465-1482.
[17] Khandelwal P, Gupta A, Sinha A, et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome [J]. Pediatr Nephrol, 2015, 30(3): 451-457.

相关文章 15

[1]	巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2]	孙红林,管玉强,于培儒,李磊,杜庆霞,丁浩. 支架植入治疗儿童主动脉缩窄并高血压的可行性及近中期疗效[J]. 山东大学学报 (医学版), 2026, 64(4): 58-62.
[3]	林明霞,刘桂斌,马燕花,连曌昱,任洋洋. ATP酶铜转运蛋白α介导的铜死亡途径及在肿瘤治疗中的价值[J]. 山东大学学报 (医学版), 2026, 64(4): 117-124.
[4]	樊呈敏,宋静雨,于书彦,毛雪琴. 舒肝解郁胶囊治疗青少年抑郁障碍的研究进展[J]. 山东大学学报 (医学版), 2026, 64(3): 17-23.
[5]	李雪凯,孙淋涵,刘端瑞,倪阳. 乳酸化修饰在肿瘤炎癌进程中的功能与机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 65-76.
[6]	国科,陈绪军,郑宝石,施超,黄克力,曹勇,陈军,吴东凯,张晓慎,罗俊辉,申林,莫绪明,杨岷,王晓武,雷印胜,田茂州,王振东,孟自力,孙忠东,李有金,陆辉辉,孟春营,高峰,陈黔苏,郭能瑞,柳德斌,张楠,林宇,陈文生,宋保国,方智,王海晨,廖晓波,徐朝军. 快通道拔管在全动脉冠脉旁路移植术的多中心临床效果[J]. 山东大学学报 (医学版), 2025, 63(5): 26-32.
[7]	赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 ¹³¹I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28.
[8]	韩馨玮,牛月,魏代敏. 激素替代方案准备内膜的冻胚移植前雌激素治疗时间对新生儿体质量的影响[J]. 山东大学学报 (医学版), 2025, 63(11): 46-52.
[9]	黄艳,周应芳,彭超. 青少年子宫内膜异位症的管理要点和策略[J]. 山东大学学报 (医学版), 2025, 63(10): 8-12.
[10]	薛铭,梁静,凌斌. 各种类型子宫内膜异位症疼痛特点及治疗研究进展[J]. 山东大学学报 (医学版), 2025, 63(10): 13-19.
[11]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[12]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[13]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[14]	陈忠,王盛. 主动脉疾病治疗现状及思考[J]. 山东大学学报 (医学版), 2024, 62(9): 1-6.
[15]	范立彬,张鸿坤. 腹主动脉瘤腔内修复术后Ⅱ型内漏的预防及治疗进展[J]. 山东大学学报 (医学版), 2024, 62(9): 55-60.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed